Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinase activity profile-guided targeted therapy selection in advanced solid tumors
2010-019982-27Phase 2Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib, sorafenib, erlotinib, lapatinib and dasatinib in Nonhematologic neoplasms (5 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Clinical benefit rate. Started Apr 2010; status: active.
02
Drugs
sunitinibsorafeniberlotiniblapatinibdasatinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2010-019982-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019982-27.